Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Oncothyreon ( ONTY)

Short interest: 20%
52-week high: $11.59
Current price: $5.98
Year-to-date performance relative to the Nasdaq Biotechnology Index: Up 83%

The short story is simple: 1) Cancer immunotherapy doesn't work (Dendreon's Provenge included); 2) Oncothyreon's Stimuvax lung cancer won't work either; 3) the "positive" phase 2 study of Stimuvax's enrolled too few patients and was skewed in the drug's favor; 4) Oncothyreon used to be known as Biomira -- any drug company that changes its name is an automatic short; 5) Biomira/Oncothyreon was founded and headquartered in Canada before moving to the U.S.

If you liked this article you might like

Here's How to Trade Bank of America, Freeport-McMoRan, Seagate Right Now

5 Stocks Under $10 Set to Soar

5 Biotech Stocks Under $10 Making Big Moves

5 Names Seeing Bullish Flow

Arena Pharmaceuticals And 6 More Stocks To Watch